Johnson & Johnson (JNJ) 101.14 $JNJ
National Risperdal Attorneys at The Onder Law Firm Analyze Ongoing Risperdal Lawsuit Progress
PRWeb - 1 hr 45 mins ago
Attorneys handling national Risperdal lawsuits for The Onder Law Firm report progress in the Risperdal lawsuits filed in Pennsylvania's Complex Litigation Center. According to court documents*, a Motion for Summary Judgment regarding Statute of Limitations was filed earlier this week, on Monday, May 19. This document proposes that persons filing Risperdal lawsuits who took the drug in 2006 or more recently will be considered in this court. A further meeting has been scheduled to discuss the nearly 400 Risperdal lawsuit cases pending under the title Risperdal Litigation, case number 100300296 in the Pennsylvania State Court. According to court documents, the meeting is scheduled to take place on Tuesday, July 15 at 11am. The Philadelphia Complex Litigation Center handles Mass Tort cases and is presided over by the Honorable Arnold L. New.
Johnson & Johnson to Speak at Pharmica Consulting's Portfolio and Resource Management Conference
PRWeb - 2 hrs 42 mins ago
As part of its continued service to the industry, Pharmica will host its Portfolio and Resource Management conference in Philadelphia, Pa. on October 14-15, 2014. The two-day conference will feature interactive discussions on innovative solutions to resource planning issues.
Final Glance: Medical Devices companies
AP - Wed May 21, 5:05PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Wed May 21, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Dendreon Up on Provenge Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 21, 3:40PM CDT
Dendreon (DNDN) announced that it presented data from the ProACT and IMPACT studies on Provenge at the AUA
Midday Glance: Medical Devices companies
AP - Wed May 21, 12:31PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Wed May 21, 12:31PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
Johnson & Johnson (JNJ) Crosses Pivot Point Resistance at $100.83
Comtex SmarTrend(R) - Wed May 21, 10:45AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $100.40 and have already reached the first level of resistance at $100.83. Should the shares continue to rise, the resistance pivots of $101.42 and $102.44 will be of interest.
Market Movers - Health Care Sector Stocks -- Research on VCA Antech, MEDNAX, Lannett, and Johnson & Johnson
PR Newswire - Wed May 21, 10:27AM CDT
On Tuesday, May 20, 2014, the NASDAQ Composite ended at 4,096.89, down 0.70%, the Dow Jones Industrial Average finished the day 0.83% lower at 16,374.31, and the S&P 500 closed at 1,872.83, down 0.65%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 672.04, down 0.62%, while the index has advanced 2.04% in the last one month. Investor-Edge has initiated coverage on the following equities: VCA Antech Inc. (NASDAQ: WOOF), MEDNAX Inc. (NYSE: MD), Lannett Co. Inc. (NYSE: LCI) and Johnson & Johnson (NYSE: JNJ). Free technical research on WOOF, MD, LCI and JNJ can be downloaded upon signing up at:
Dow Component Johnson & Johnson (JNJ) To Go Ex-dividend Tomorrow
at The Street - Wed May 21, 10:00AM CDT
Thursday, May 22, 2014 is the ex-dividend date for Dow component (NYSE:JNJ).
Early Glance: Pharmaceuticals companies
AP - Wed May 21, 9:22AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Wed May 21, 9:22AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are up at 10 a.m.:
Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth
PR Newswire - Wed May 21, 7:41AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Celgene Corporation (NASDAQ: CELG), Novartis AG (NYSE: NVS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2747-100free.
Global and Chinese Monoclonal Antibody Industry Forecasts Report, 2013-2017
M2 - Wed May 21, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9lnwhr/global_and) has announced the addition of the "Global and Chinese Monoclonal Antibody Industry Forecasts Report, 2013-2017" report to their offering. In September 2013, the Infliximab generic drug - Inflectra developed by South Korea Celltrion and the U.S. Hospira jointly was launched upon the approval of the EU EMA. In November 2013, the Trastuzumab generic drug developed by the U.S. Mylan and India Biocon together was available in the market under the permit of Drug Controller General Of India. Mylan will sell the product tagged with the brand name Hertraz in India in early 2014. In addition, India Biocon's first anti-CD6 Alzumab (Itolizumab) for the treatment of chronic plaque psoriasis was approved to be sold in India in August 2013. In recent years, China monoclonal antibody industry has been developing fast with the market size CAGR of 44.6% in 2010-2012. More than 100 companies have been involved in monoclonal antibody agents, and 10 ones of them have conducted clinical applications. The Chinese market is dominated by Rituximab, Trastuzumab, Infliximab, Bevacizumab and other imported products, all of which occupied 70-75% market share totally in 2012. However, by virtue of price and geographical advantages, the competitiveness of Chinese local monoclonal antibody products has been gradually improved, such as the competition between Nimotuzumab and Cetuximab. The market share of Merck's Cetuximab in China shrinks and was excluded from top 200 drugs purchased by Chinese 22 typical urban hospitals in 2012 with the value of RMB130 million (down 16.35% year on year). Meanwhile, the R & D of monoclonal antibody has also made progress. The Adalimumab generic drug developed by Huahai Pharmaceutical and American Oncobiologics jointly was ratified by the EU EMA and the U.S. FDA in December 2013 and the clinical trial Phase I was implemented. The Trastuzumab generic drug of Genor Biopharma was granted with Australian Clinical Preliminary Summary Report Phase I in August 2012 and SFDA's clinical trial approval in July 2013. The key topics covered by this report include: - Status quo, market size, competition pattern and development forecast of the global monoclonal antibody industry; - Status quo, market size, competition pattern and development forecast of China monoclonal antibody industry; - Operation, monoclonal antibody business, development in China and R & D of six global and 10 Chinese monoclonal antibody companies. Key Topics Covered: 1 Overview of Monoclonal Antibody Industry 2 Overview of Global Monoclonal Antibody Industry 3 Chinese Monoclonal Antibody Market 4 Key Foreign Monoclonal Antibody Agent Enterprises 5 Key Chinese Monoclonal Antibody Agent Enterprises 6 Summary and Forecast Companies Mentioned - AbbVie - Amgen - Beijing Biotech Pharmaceutical Co., Ltd. - Beijing SL Pharmaceutical Co., Ltd. - Chengdu Huasun Group Co., Ltd. - Huahai Pharmaceutical Co., Ltd. - Johnson & Johnson - Merck - NVS - Roche Pharmaceuticals - Shanghai CP GuoJian Biotech Academy - Shanghai CP Guojian Pharmaceutical Co., Ltd. - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. - Shanghai Guosheng Pharmaceutical Co., Ltd. - Shanghai Lansheng States Kin Pharmaceutical Co., Ltd. - Shanghai Medipharm Biotech Co., Ltd. - Shanghai Zhangjiang Biotech Co., Ltd. - Shenzhen Main Luck Pharmaceuticals Inc. - Yunnan Walvax Biotechnology Co., Ltd. - Zhejiang Hisun Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9lnwhr/global_and
Why I'm Still Avoiding Dendreon
Brian Nichols, The Motley Fool - Motley Fool - Tue May 20, 11:36AM CDT
Investors sold the news of Dendreon 's first-quarter earnings and the company's very slight year-over-year revenue growth, although the stock has more recently risen on the announcement of a Provenge abstract presentation . With $68.8 million in...
National Risperdal Attorneys at The Onder Law Firm Analyze Ongoing Risperdal Lawsuit Progress
PRWeb - 1 hr 45 mins ago
Attorneys handling national Risperdal lawsuits for The Onder Law Firm report progress in the Risperdal lawsuits filed in Pennsylvania's Complex Litigation Center. According to court documents*, a Motion for Summary Judgment regarding Statute of Limitations was filed earlier this week, on Monday, May 19. This document proposes that persons filing Risperdal lawsuits who took the drug in 2006 or more recently will be considered in this court. A further meeting has been scheduled to discuss the nearly 400 Risperdal lawsuit cases pending under the title Risperdal Litigation, case number 100300296 in the Pennsylvania State Court. According to court documents, the meeting is scheduled to take place on Tuesday, July 15 at 11am. The Philadelphia Complex Litigation Center handles Mass Tort cases and is presided over by the Honorable Arnold L. New.
Johnson & Johnson to Speak at Pharmica Consulting's Portfolio and Resource Management Conference
PRWeb - 2 hrs 42 mins ago
As part of its continued service to the industry, Pharmica will host its Portfolio and Resource Management conference in Philadelphia, Pa. on October 14-15, 2014. The two-day conference will feature interactive discussions on innovative solutions to resource planning issues.
Final Glance: Medical Devices companies
AP - Wed May 21, 5:05PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Wed May 21, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Dendreon Up on Provenge Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 21, 3:40PM CDT
Dendreon (DNDN) announced that it presented data from the ProACT and IMPACT studies on Provenge at the AUA
Midday Glance: Medical Devices companies
AP - Wed May 21, 12:31PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Wed May 21, 12:31PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
Johnson & Johnson (JNJ) Crosses Pivot Point Resistance at $100.83
Comtex SmarTrend(R) - Wed May 21, 10:45AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $100.40 and have already reached the first level of resistance at $100.83. Should the shares continue to rise, the resistance pivots of $101.42 and $102.44 will be of interest.
Market Movers - Health Care Sector Stocks -- Research on VCA Antech, MEDNAX, Lannett, and Johnson & Johnson
PR Newswire - Wed May 21, 10:27AM CDT
On Tuesday, May 20, 2014, the NASDAQ Composite ended at 4,096.89, down 0.70%, the Dow Jones Industrial Average finished the day 0.83% lower at 16,374.31, and the S&P 500 closed at 1,872.83, down 0.65%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 672.04, down 0.62%, while the index has advanced 2.04% in the last one month. Investor-Edge has initiated coverage on the following equities: VCA Antech Inc. (NASDAQ: WOOF), MEDNAX Inc. (NYSE: MD), Lannett Co. Inc. (NYSE: LCI) and Johnson & Johnson (NYSE: JNJ). Free technical research on WOOF, MD, LCI and JNJ can be downloaded upon signing up at:
Dow Component Johnson & Johnson (JNJ) To Go Ex-dividend Tomorrow
at The Street - Wed May 21, 10:00AM CDT
Thursday, May 22, 2014 is the ex-dividend date for Dow component (NYSE:JNJ).
Early Glance: Pharmaceuticals companies
AP - Wed May 21, 9:22AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Wed May 21, 9:22AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are up at 10 a.m.:
Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth
PR Newswire - Wed May 21, 7:41AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Celgene Corporation (NASDAQ: CELG), Novartis AG (NYSE: NVS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2747-100free.
Global and Chinese Monoclonal Antibody Industry Forecasts Report, 2013-2017
M2 - Wed May 21, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9lnwhr/global_and) has announced the addition of the "Global and Chinese Monoclonal Antibody Industry Forecasts Report, 2013-2017" report to their offering. In September 2013, the Infliximab generic drug - Inflectra developed by South Korea Celltrion and the U.S. Hospira jointly was launched upon the approval of the EU EMA. In November 2013, the Trastuzumab generic drug developed by the U.S. Mylan and India Biocon together was available in the market under the permit of Drug Controller General Of India. Mylan will sell the product tagged with the brand name Hertraz in India in early 2014. In addition, India Biocon's first anti-CD6 Alzumab (Itolizumab) for the treatment of chronic plaque psoriasis was approved to be sold in India in August 2013. In recent years, China monoclonal antibody industry has been developing fast with the market size CAGR of 44.6% in 2010-2012. More than 100 companies have been involved in monoclonal antibody agents, and 10 ones of them have conducted clinical applications. The Chinese market is dominated by Rituximab, Trastuzumab, Infliximab, Bevacizumab and other imported products, all of which occupied 70-75% market share totally in 2012. However, by virtue of price and geographical advantages, the competitiveness of Chinese local monoclonal antibody products has been gradually improved, such as the competition between Nimotuzumab and Cetuximab. The market share of Merck's Cetuximab in China shrinks and was excluded from top 200 drugs purchased by Chinese 22 typical urban hospitals in 2012 with the value of RMB130 million (down 16.35% year on year). Meanwhile, the R & D of monoclonal antibody has also made progress. The Adalimumab generic drug developed by Huahai Pharmaceutical and American Oncobiologics jointly was ratified by the EU EMA and the U.S. FDA in December 2013 and the clinical trial Phase I was implemented. The Trastuzumab generic drug of Genor Biopharma was granted with Australian Clinical Preliminary Summary Report Phase I in August 2012 and SFDA's clinical trial approval in July 2013. The key topics covered by this report include: - Status quo, market size, competition pattern and development forecast of the global monoclonal antibody industry; - Status quo, market size, competition pattern and development forecast of China monoclonal antibody industry; - Operation, monoclonal antibody business, development in China and R & D of six global and 10 Chinese monoclonal antibody companies. Key Topics Covered: 1 Overview of Monoclonal Antibody Industry 2 Overview of Global Monoclonal Antibody Industry 3 Chinese Monoclonal Antibody Market 4 Key Foreign Monoclonal Antibody Agent Enterprises 5 Key Chinese Monoclonal Antibody Agent Enterprises 6 Summary and Forecast Companies Mentioned - AbbVie - Amgen - Beijing Biotech Pharmaceutical Co., Ltd. - Beijing SL Pharmaceutical Co., Ltd. - Chengdu Huasun Group Co., Ltd. - Huahai Pharmaceutical Co., Ltd. - Johnson & Johnson - Merck - NVS - Roche Pharmaceuticals - Shanghai CP GuoJian Biotech Academy - Shanghai CP Guojian Pharmaceutical Co., Ltd. - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. - Shanghai Guosheng Pharmaceutical Co., Ltd. - Shanghai Lansheng States Kin Pharmaceutical Co., Ltd. - Shanghai Medipharm Biotech Co., Ltd. - Shanghai Zhangjiang Biotech Co., Ltd. - Shenzhen Main Luck Pharmaceuticals Inc. - Yunnan Walvax Biotechnology Co., Ltd. - Zhejiang Hisun Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9lnwhr/global_and
Why I'm Still Avoiding Dendreon
Brian Nichols, The Motley Fool - Motley Fool - Tue May 20, 11:36AM CDT
Investors sold the news of Dendreon 's first-quarter earnings and the company's very slight year-over-year revenue growth, although the stock has more recently risen on the announcement of a Provenge abstract presentation . With $68.8 million in...
